Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Journal of Hematology & Oncology
Published in: Journal of Hematology & Oncology 1/2016

Open Access 01-12-2016 | Case report

Programmed cell death-1 blockade in recurrent disseminated Ewing sarcoma

Authors: Georgia J. B. McCaughan, Michael J. Fulham, Annabelle Mahar, Judy Soper, Angela M. Hong, Paul D. Stalley, Martin H. N. Tattersall, Vivek A. Bhadri

Published in: Journal of Hematology & Oncology | Issue 1/2016

Login to get access

Abstract

Background

Ewing sarcoma (EWS) is a malignant tumour of bone and soft tissue, and although many patients are cured with conventional multimodal therapy, those with recurrent or metastatic disease have a poor prognosis. Genomic instability and programmed cell death ligand-1 (PD-L1) expression have been identified in EWS, providing a rationale for treatment with agents that block the programmed cell death-1 (PD-1) receptor.

Case presentation

In this report, we describe a heavily pre-treated patient with recurrent metastatic EWS who achieved a clinical and radiological remission with PD-1 blockade.

Conclusions

To our knowledge, this is the first reported case demonstrating efficacy of PD-1 blockade in EWS. This warrants further investigation in particular given the poor prognosis in patients with recurrent or metastatic disease.
Literature
1.
de Alava ELS. Sorensen PH Chapter 19: Ewing sarcoma. In: Fletcher CDM BJ, Hogendoorn PCW, Mertens F, editors. WHO Classification of Tumours of Soft Tissue and Bone. Lyon: IARC; 2013.
2.
Gurney GJ SA, Bulterys M. Malignant bone tumours. Bethesda, MD: National Cancer Institute, SEER Program; 1999. NIH Pub No. 99-4649; 1999.
3.
Gaspar N, Hawkins DS, Dirksen U, et al. Ewing sarcoma: current management and future approaches through collaboration. J Clin Oncol. 2015;33:3036–46.CrossRefPubMed
4.
Rodriguez-Galindo C, Billups CA, Kun LE, et al. Survival after recurrence of Ewing tumors: the St Jude Children’s Research Hospital experience, 1979–1999. Cancer. 2002;94:561–9.CrossRefPubMed
5.
Bacci G, Ferrari S, Longhi A, et al. Therapy and survival after recurrence of Ewing’s tumors: the Rizzoli experience in 195 patients treated with adjuvant and neoadjuvant chemotherapy from 1979 to 1997. Ann Oncol. 2003;14:1654–9.CrossRefPubMed
6.
Barker LM, Pendergrass TW, Sanders JE, Hawkins DS. Survival after recurrence of Ewing’s sarcoma family of tumors. J Clin Oncol. 2005;23:4354–62.CrossRefPubMed
7.
8.
Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372:2018–28.CrossRefPubMed
9.
Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372:320–30.CrossRefPubMed
10.
Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med. 2015;372:311–9.CrossRefPubMedPubMedCentral
11.
12.
Ohali A, Avigad S, Cohen IJ, et al. High frequency of genomic instability in Ewing family of tumors. Cancer Genet Cytogenet. 2004;150:50–6.CrossRefPubMed
13.
Ferreira BI, Alonso J, Carrillo J, et al. Array CGH and gene-expression profiling reveals distinct genomic instability patterns associated with DNA repair and cell-cycle checkpoint pathways in Ewing’s sarcoma. Oncogene. 2008;27:2084–90.CrossRefPubMed
14.
Raj S, Bui M, Gonzales R, Letson D, Antonia SJ. Impact of PDL1 expression on clinical outcomes in subtypes of sarcoma. Ann Oncol. 2014;25:iv494–510.
15.
Kozak KS-CA, Rembiszewska A, Podgorska A, Kosela Patercyzyk HM, Przby J, Gos A, Switaj T, Prochorec-Sobieszek M, Rutkowski P. Programmed death ligand-1 (PD-L1) expression and prognostic value in synovial sarcoma. Ann Oncol. 2014;25(Supplement 4):494–510.
16.
Kim JR, Moon YJ, Kwon KS, et al. Tumor infiltrating PD1-positive lymphocytes and the expression of PD-L1 predict poor prognosis of soft tissue sarcomas. PLoS One. 2013;8:e82870.CrossRefPubMedPubMedCentral
17.
Herbst RS, Soria JC, Kowanetz M, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515:563–7.CrossRefPubMedPubMedCentral
18.
Grosso J HC, Inzunza D, Cardona DM, Simon JS, Gupta AK, Sankar V, Park J, Kollia G, Taube JM, Anders R, Jure-Kunkel M, Novotny J, Jr., Taylor CR, Zhang X, Phillips T, Pauline Simmons P and Cogswell J. Association of tumor PD-L1 expression and immune biomarkers with clinical activity in patients (pts) with advanced solid tumors treated with nivolumab (anti-PD-1; BMS-936558; ONO-4538). J Clin Oncol 2013;31 (suppl; abstr 3016).
19.
Nghiem PT, Bhatia S, Lipson EJ, et al. PD-1 Blockade with pembrolizumab in advanced Merkel-cell carcinoma. New Engl J Med 2016. [Epub ahead of print].
20.
Topalian SL, Taube JM, Anders RA, Pardoll DM. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer. 2016;16:275–87.CrossRefPubMed
21.
22.
Chen KH, Yuan CT, Tseng LH, Shun CT, Yeh KH. Case report: mismatch repair proficiency and microsatellite stability in gastric cancer may not predict programmed death-1 blockade resistance. J Hematol Oncol. 2016;9:29.CrossRefPubMedPubMedCentral
23.
24.
Deng L, Liang H, Burnette B, et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest. 2014;124:687–95.CrossRefPubMedPubMedCentral
25.
Leavey PJ, Mascarenhas L, Marina N, et al. Prognostic factors for patients with Ewing sarcoma (EWS) at first recurrence following multi-modality therapy: a report from the Children’s Oncology Group. Pediatr Blood Cancer. 2008;51:334–8.CrossRefPubMedPubMedCentral
26.
Burgess MA CJ, Reinke DK, Riedel RF, George S, Movva S, Van Tine BA, Davis LE, Schuetze S, Hu J, Attia S, Priebat DA, Reed DR, D’Angelo SP, Okuno SH, Maki RG, Patel S, Baker LH, Tawbi HA. SARC 028: A phase II study of the anti-PD1 antibody pembrolizumab (P) in patients (Pts) with advanced sarcomas. J Clin Oncol. 2015;33 (suppl; abstr TPS10578).
Metadata
Title
Programmed cell death-1 blockade in recurrent disseminated Ewing sarcoma
Authors
Georgia J. B. McCaughan
Michael J. Fulham
Annabelle Mahar
Judy Soper
Angela M. Hong
Paul D. Stalley
Martin H. N. Tattersall
Vivek A. Bhadri
Publication date
01-12-2016
Publisher
BioMed Central
Published in
Journal of Hematology & Oncology / Issue 1/2016
Electronic ISSN: 1756-8722
DOI
https://doi.org/10.1186/s13045-016-0278-x

Other articles of this Issue 1/2016

Journal of Hematology & Oncology 1/2016 Go to the issue

Research

Proteasome subunit expression analysis and chemosensitivity in relapsed paediatric acute leukaemia patients receiving bortezomib-containing chemotherapy

Letter to the Editor

Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy

Case report

Ruxolitinib in steroid refractory graft-vs.-host disease: a case report

Review

Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy

Rapid communication

PU.1 controls the expression of long noncoding RNA HOTAIRM1 during granulocytic differentiation

Research

H2S protects against fatal myelosuppression by promoting the generation of megakaryocytes/platelets
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits